Insider Trading & Ownership of Paul B. Manning

Location
Charlottesville, VA
Summary
The estimated net worth of Paul B. Manning is at least $95,556,393 dollars as of 02 Apr 2026. Paul B. Manning is the Director of Candel Therapeutics, Inc. and owns shares of Candel Therapeutics, Inc. (CADL) stock worth about $33.27M. Paul B. Manning is the Director, 10%+ Owner of Verrica Pharmaceuticals Inc. and owns shares of Verrica Pharmaceuticals Inc. (VRCA) stock worth about $32.17M. Paul B. Manning is the Director of Liquidia Corp and owns shares of Liquidia Corp (LQDA) stock worth about $20.02M. Paul B. Manning is the 10%+ Owner of Taysha Gene Therapies, Inc. and owns shares of Taysha Gene Therapies, Inc. (TSHA) stock worth about $7.81M. Paul B. Manning is the 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $2.28M.
Signature
/s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Paul B. Manning and return when a new Insider Trading filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Quick Takeaways

  • Paul B. Manning has 5 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $95,556,393.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Candel Therapeutics, Inc. ($33,268,209).
  • Past-year value change for that position: +$2,999,996.

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Official SEC Source

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Paul B. Manning

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CADL Candel Therapeutics, Inc. Director $33,268,209 +$2,999,996 +9.9% 31 Mar 2026
VRCA Verrica Pharmaceuticals Inc. Director, 10%+ Owner $32,171,572 +$17,505,157 +119% 25 Nov 2025
LQDA Liquidia Corp Director $20,018,323 -$18,957,475 -49% 11 Feb 2026
TSHA Taysha Gene Therapies, Inc. 10%+ Owner $7,814,686 +$2,062,500 +36% 30 May 2025
ABOS Acumen Pharmaceuticals, Inc. 10%+ Owner $2,283,603 06 Jul 2021

Insider Transactions Reported by Paul B. Manning:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored